Strateos Closes $56 Million Series B Financing to Accelerate the Roll-Out of its SmartLab of the Future Platform

New financing led by DCVC and Lux Capital, will expand the next generation of smart lab solutions with direct access to automation to accelerate discovery in the life sciences

Strateos, Inc., a pioneer in the development of remote access laboratories and lab control software for life science research, today announced the closing of its $56.1 million Series B financing led by DCVC and Lux Capital with participation from new investors including Eli Lilly and Company, Ally Bridge Group, Black Diamond Ventures, Mack & Co., LLC, and Castor Ventures. With this financing, Strateos will continue to drive innovations on its SmartLab Platform™, which integrates data generation and AI-enablement with its unique and flexible automation to accelerate pharmaceutical and synthetic biology R&D.

"Life science research needs faster, more reliable and lower cost data to fully leverage artificial intelligence-powered analysis tools," said Mark Fischer-Colbrie, CEO at Strateos. "Our unique fleet of lab automation modules, which can be accessed from anywhere in the world, speed the design-make-test-analyze cycle and generate clean, AI-enabled data. Strateos is pleased to have the backing of these world-class investors who bring deep expertise in building and scaling innovative platforms at the intersection of the life sciences and information technology. With their support, Strateos is re-imagining the world of life science research and ushering in a new era of decentralized discovery."

Leave a Comment